{
  "first_published_at": "2012-09-25", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON185628", 
  "title": "Dipeptidylpeptidase-4 inhibitors (‘gliptins’): risk of acute pancreatitis", 
  "tags": "{\"parsed_therapeutic\": [\"endocrinology-diabetology-metabolism\"], \"Audience:\": [\"Primary care\"], \"Therapeutic area:\": [\"Endocrinology, diabetology and metabolism\"]}", 
  "_document_number": 100, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "endocrinology-diabetology-metabolism"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Dipeptidylpeptidase-4 inhibitors (&#8216;gliptins&#8217;): risk of acute pancreatitis</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: September 2012</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>There have been reports of acute pancreatitis associated with drugs in the dipeptidylpeptidase-4 (DPP-4) inhibitor class of antidiabetic agents (&#8216;gliptins&#8217;). Patients should be informed of the characteristic symptoms of acute pancreatitis &#8211; persistent, severe abdominal pain (sometimes radiating to the back) &#8211; and encouraged to tell their healthcare provider if they have such symptoms. If pancreatitis is suspected, the DPP-4 inhibitor and other potentially suspect medicinal products should be discontinued.<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>DPP-4 inhibitors are indicated for the improvement of glycaemic control in adults with type 2 diabetes mellitus. Drugs of this class include Onglyza&#9660; (saxagliptin), Trajenta&#9660; (linagliptin), Galvus&#9660; (vildagliptin) and Januvia (sitagliptin). A number of fixed-dose combination tablets containing a DDP-4 inhibitor with metformin are also available, including Eucreas&#9660; (vildagliptin) and Janumet (sitagliptin).</p>\n\n<h3>Risk of pancreatitis</h3>\n\n<p>An increased risk of acute pancreatitis has been identified for all approved DPP-4 inhibitors. For most of the compounds this was detected in spontaneous post-marketing reports; for one of the newer compounds, linagliptin, a small increased number of cases compared with placebo was detected in clinical development.</p>\n\n<p>Consequently, pancreatitis is now included in the <a href=\" http://www.medicines.org.uk/EMC/default.aspx\" target=\"_blank\">product information</a> for all DPP-4 inhibitors as a possible adverse reaction. The reporting rate of pancreatitis appears to be low (ranging between 1/1 000 and 1/100 patients receiving the drug) but the precise frequency is unknown as few cases have been reported in clinical trials. In most cases, pancreatitis resolved after discontinuation of treatment.</p>\n\n<p>The possible mechanism leading to acute pancreatitis is not clear. Data from animal studies have been inconclusive or have not suggested a safety concern. In addition, patients with diabetes are known to have a higher incidence of pancreatitis compared with non-diabetic patients.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Patients treated with DDP-4 inhibitors should be informed of the characteristic symptoms of acute pancreatitis &#8211; persistent, severe abdominal pain (sometimes radiating to the back) &#8211; and encouraged to tell their healthcare provider if they have such symptoms.</li>\n\n<li>If pancreatitis is suspected, the DPP-4 inhibitor and other potentially suspect medicines should be discontinued</li>\n\n<li>Report suspected adverse reactions through the Yellow Card Scheme&#8212;see <a target=\"_blank\" href=\"www.mhra.gov.uk/yellowcard\">www.mhra.gov.uk/yellowcard</a>. When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, and treatment dates.<br />\n</li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p><a href=\" http://guidance.nice.org.uk/CG87\" target=\"_blank\">NICE guidance on the treatment of type 2 diabetes</a></p>\n\n<p>BNF section 6.1.2. <a href=\"http://www.medicinescomplete.com/mc/bnf/current/4163.htm\" target=\"_blank\">Antidiabetic drugs</a></p>\n\n<p><em>Article citation: Drug Safety Update September 2012, vol 6, issue 2: A3</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>DPP-4 inhibitors are indicated for the improvement of glycaemic control in adults with type 2 diabetes mellitus. Drugs of this class include Onglyza&#9660; (saxagliptin), Trajenta&#9660; (linagliptin), Galvus&#9660; (vildagliptin) and Januvia (sitagliptin). A number of fixed-dose combination tablets containing a DDP-4 inhibitor with metformin are also available, including Eucreas&#9660; (vildagliptin) and Janumet (sitagliptin).</p>\n\n<h3>Risk of pancreatitis</h3>\n\n<p>An increased risk of acute pancreatitis has been identified for all approved DPP-4 inhibitors. For most of the compounds this was detected in spontaneous post-marketing reports; for one of the newer compounds, linagliptin, a small increased number of cases compared with placebo was detected in clinical development.</p>\n\n<p>Consequently, pancreatitis is now included in the <a href=\"http://www.medicines.org.uk/EMC/default.aspx\" target=\"_blank\">product information</a> for all DPP-4 inhibitors as a possible adverse reaction. The reporting rate of pancreatitis appears to be low (ranging between 1/1 000 and 1/100 patients receiving the drug) but the precise frequency is unknown as few cases have been reported in clinical trials. In most cases, pancreatitis resolved after discontinuation of treatment.</p>\n\n<p>The possible mechanism leading to acute pancreatitis is not clear. Data from animal studies have been inconclusive or have not suggested a safety concern. In addition, patients with diabetes are known to have a higher incidence of pancreatitis compared with non-diabetic patients.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Patients treated with DDP-4 inhibitors should be informed of the characteristic symptoms of acute pancreatitis &#8211; persistent, severe abdominal pain (sometimes radiating to the back) &#8211; and encouraged to tell their healthcare provider if they have such symptoms.</li>\n\n<li>If pancreatitis is suspected, the DPP-4 inhibitor and other potentially suspect medicines should be discontinued</li>\n\n<li>Report suspected adverse reactions through the Yellow Card Scheme&#8212;see <a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/www.mhra.gov.uk/yellowcard\">www.mhra.gov.uk/yellowcard</a>. When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, and treatment dates.<br>\n</li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p><a href=\"http://guidance.nice.org.uk/CG87\" target=\"_blank\">NICE guidance on the treatment of type 2 diabetes</a></p>\n\n<p>BNF section 6.1.2. <a href=\"http://www.medicinescomplete.com/mc/bnf/current/4163.htm\" target=\"_blank\">Antidiabetic drugs</a></p>\n\n<p><em>Article citation: Drug Safety Update September 2012, vol 6, issue 2: A3</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2012-09-01", 
  "date_last_modified": "2013-02-05", 
  "_assets": [], 
  "_item_id": 100, 
  "summary": "There have been reports of acute pancreatitis associated with drugs in the dipeptidylpeptidase-4 (DPP-4) inhibitor class of antidiabetic agents (‘gliptins’). Patients should be informed of the characteristic symptoms of acute pancreatitis – persistent, severe abdominal pain (sometimes radiating to the back) – and encouraged to tell their healthcare provider if they have such symptoms. If pancreatitis is suspected, the DPP-4 inhibitor and other potentially suspect medicinal products should be discontinued.", 
  "body": "Article date: September 2012\n\nDPP-4 inhibitors are indicated for the improvement of glycaemic control in adults with type 2 diabetes mellitus. Drugs of this class include Onglyza▼ (saxagliptin), Trajenta▼ (linagliptin), Galvus▼ (vildagliptin) and Januvia (sitagliptin). A number of fixed-dose combination tablets containing a DDP-4 inhibitor with metformin are also available, including Eucreas▼ (vildagliptin) and Janumet (sitagliptin).\n\n### Risk of pancreatitis\n\nAn increased risk of acute pancreatitis has been identified for all approved DPP-4 inhibitors. For most of the compounds this was detected in spontaneous post-marketing reports; for one of the newer compounds, linagliptin, a small increased number of cases compared with placebo was detected in clinical development.\n\nConsequently, pancreatitis is now included in the [product information](http://www.medicines.org.uk/EMC/default.aspx) for all DPP-4 inhibitors as a possible adverse reaction. The reporting rate of pancreatitis appears to be low (ranging between 1/1 000 and 1/100 patients receiving the drug) but the precise frequency is unknown as few cases have been reported in clinical trials. In most cases, pancreatitis resolved after discontinuation of treatment.\n\nThe possible mechanism leading to acute pancreatitis is not clear. Data from animal studies have been inconclusive or have not suggested a safety concern. In addition, patients with diabetes are known to have a higher incidence of pancreatitis compared with non-diabetic patients.\n\nAdvice for healthcare professionals:  \n  \n  * Patients treated with DDP-4 inhibitors should be informed of the characteristic symptoms of acute pancreatitis – persistent, severe abdominal pain (sometimes radiating to the back) – and encouraged to tell their healthcare provider if they have such symptoms.  \n  * If pancreatitis is suspected, the DPP-4 inhibitor and other potentially suspect medicines should be discontinued  \n  * Report suspected adverse reactions through the Yellow Card Scheme—see [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/www.mhra.gov.uk/yellowcard). When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, and treatment dates.  \n  \n  \nFurther information:\n\n[NICE guidance on the treatment of type 2 diabetes](http://guidance.nice.org.uk/CG87)\n\nBNF section 6.1.2. [Antidiabetic drugs](http://www.medicinescomplete.com/mc/bnf/current/4163.htm)\n\nArticle citation: Drug Safety Update September 2012, vol 6, issue 2: A3\n"
}